| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
286,499 |
77,320 |
$36.39M |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
285,586 |
80,951 |
$35.94M |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
367,787 |
103,898 |
$11.93M |
| U0004 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r |
108,756 |
32,900 |
$6.29M |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
51,913 |
16,919 |
$947K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
29,854 |
12,927 |
$265K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
888 |
870 |
$32K |
| 86328 |
|
14 |
14 |
$271.38 |
| 87801 |
Infectious agent detection by nucleic acid; amplified probe, multiple organisms |
349 |
115 |
$131.02 |
| 87481 |
|
117 |
115 |
$32.75 |
| 87500 |
|
30 |
30 |
$0.00 |
| 87640 |
|
49 |
49 |
$0.00 |
| 87471 |
|
48 |
48 |
$0.00 |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
49 |
49 |
$0.00 |
| 87551 |
|
48 |
48 |
$0.00 |
| 87641 |
|
49 |
49 |
$0.00 |
| 87653 |
|
49 |
49 |
$0.00 |
| 87150 |
|
337 |
30 |
$0.00 |